Log in to your Inderes Free account to see all free content on this page.

Relesys

Under 1K följer bolaget

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Gratisanvändare
Stock market's most popular morning newsletter
Tillgång till analytikerkommentarer och rekommendationer
Vårt eget aktiescreeningsverktyg
Premiumanvändare
Alla aktieanalyser och övrigt innehåll
Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)
Inderes modellportfölj
Aktieanalys utförd av tredje part

Relesys: Copilot to acquire all shares at DKK 6.60/share - ABG

37% premium to date of strategic review, 8% discount to last close Equates to '24e-'26e EV/ARR of 4.0-2.4x; within DKK 3.3-9.0 FVR Requests removal from Nasdaq within 2-3 weeks Copilot to acquire all shares at DKK 6.60/share Relesys tonight announced...

Aktieanalys utförd av tredje part

Relesys: Entering '24 with strong momentum - ABG

37% y-o-y ARR growth with 118% NRR in Q4 Lifting '24e-'26e ARR by 6-8%, EBITDA largely unchanged New FVR of DKK 3.3-9.0 (3.1-8.4) 37% y-o-y ARR growth with 118% NRR in Q4 Relesys delivered a strong Q4, seeing 37% y-o-y ARR growth to DKK 61.9m (+1% vs...

Aktieanalys utförd av tredje part

Relesys: FY'24 guidance better than expected - ABG

Guides for 34-42% FY'24 ARR growth (vs. ABGSCe at 30%) No outlook comments - we await the annual report later today Cons to lift '24 ARR by 4-10%, profitability likely by more Sets FY'24 ARR and revenue guidance Today, Relesys has announced its FY'24...

Aktieanalys utförd av tredje part

Relesys: In for a strong end to the year - ABG

Q4e: 36% y-o-y ARR growth, costs higher than in Q3 Focus on '24e: We expect 30% ARR growth and DKK -6.0m EBITDA Minor '24e-'25e top-line revisions, EBITDA up 10-4%: FVR 3.1-8.4 Q4e: 36% y-o-y ARR growth, costs higher than in Q3 We forecast Q4e ARR of...

Aktieanalys utförd av tredje part

Relesys: Cost levels to normalise after abnormal Q3 - ABG

ARR in line (36% y-o-y growth); minor '23e-'25e top-line revisions '23e EBITDA up 8% on abnormally low Q3 costs and slower hirings Small '24e-'25e EBITDA revisions; positive long-term view reiterated Minor '23e-'25e top-line revisions on reiterated guidance...

Aktieanalys utförd av tredje part

Relesys: Likely better Q3 profitability before Q4 ramp-up - ABG

Q3e: 36.5% y-o-y ARR growth A seasonally weaker quarter, but profitability likely better Limited estimate revisions; FVR of DKK 3.1-8.4 Q3e: 36.5% y-o-y ARR growth We forecast Q3e ARR of DKK 54.9m for 36.5% y-o-y growth, driven by 3.5% y-o-y ARR churn...

Aktieanalys utförd av tredje part

Relesys: Initiates strategic review - ABG

Initiates strategic review to evaluate funding and ownership No timeline; FY'23 guidance unchanged Wording leaves many scenarios open (M&A, capital raise, etc.) What has happened? Today Relesys' BoD has decided to initiate a strategic review, seeking...

Aktieanalys utförd av tredje part

Relesys: A mixed bag, but with a few more negatives - ABG

DKK 51.8m ARR ~3% below ABGSCe, 17% adj. EBITDA beat Limited ARR estimate revisions, '24e-'25e adj. EBITDA cut 1-6% FVR of DKK 3.2-8.5 Limited '23e-'25e ARR revisions despite weaker Q2 DARR We make minor revisions to '23e-'25e ARR (<1%) and continue ...